18 January 2012

INFA Group owns assets in Italy (Labochim and Sifavitor) and in Spain (Derivados Quimicos).  All sites are FDA-acceptable and they offer contract manufacturing opportunities based on a total reaction volume of almost 180’000 US gal (exactly 670 m3).

INFA owns Technologies and capabilities addressing hazardous chemistries in cGMP European Plants:
·        Sodium metallic: up to 330 lb. (150 Kg) per batch
·        Bromine: up to 3’300 lb. (1500 Kg) per batch
·        Chlorine: up to 3’300 lb. (1500 Kg) per batch
·        Cyanide: up to 2’200 lb. (1000 Kg) per batch
·        Large scale Hydrogenations (10 reactors, total volume 4’400 gal -16.7 m3 from 50 to 10 bar)
·        Large scale oxidation with H2O2 and MnO2

INFA has invested in Greener Chemistry (better environment - lower cost):
·        Large scale product purification using nanofiltration and reverse osmosis
·        Solvent recovery through pervaporation membranes

INFA has developed new technologies for large scale productions
·        Biotransformations

Infa regards Life Sciences and contract manufacturing product supply to Western Pharmaceutical companies as a viable and growing business, in a long term perspective, thanks to its highly experienced R&D Team, the close cooperation with four European Universities and strong regulatory and customer oriented service team:
·        63 US DMFs
·        13 Japanese DMFs
·        29 COS/CEP (5 pending)
·        146 products: 120 APIs (4 on exclusive basis) and 26 intermediates (all exclusive)
·        Total capacity output more than 2’200 Metric Tons!

 

Please visit the Infa website at www.infagroup.com to learn more!

 

 

18 October 2011

Please Visit Austin Chemical at the following upcoming events:

• Informex 2012 (February 14 - 17, New Orleans) - Booth 1217:  The Austin Team

 

Additionally, we wish to express our appreciation to both our customers and suppliers for helping make the below recently-attended industry events a success. 

• AAPS 2011 (October 24 - 26, Washington D.C.)  - Booth 1241 [Domino Specialty Ingredients]:  Katherine Mountain

• CPhI Europe (October 25 - 28, Frankfurt) - Booth 30D26 [Micro-Macinazione]:  Iver J. Berry, Maurice Baillargeon, Keith Dosch, John Priestland

• The Society of Petroleum Engineers Conference 2011 (October 31 - November 2, Denver) - Booth 526 [AllessaChemie]:  David Pagor

 

 

18 September 2011

(September 15, 2011) GRONINGEN, THE NETHERLANDS - Syncom announced today that it has been selected by Pfizer as the winner of the 2nd Route Design Innovation Award, which recognizes excellence and creativity in chemical process research and development.  Syncom's contribution has been judged as being the most innovative proposal received in the challenge.  Pfizer will present the award to Syncom during the 2011 ChemOutsourcing Conference to be held in Long Branch, NJ September 12 - 15.

 

The innovation challenge was initiated by Pfizer to generate new and improved routes of synthesis for the manufacture of Active Pharmaceutical Ingredients (API's) and intermediates.  For a specific Pfizer API, Syncom designed several novel and innovative routes to improve the current API manufacturing process.  The winning Syncom route provides solutions in dealing with hazardous chemicals and creates the opportunity for significant cost of goods savings.

 

"We are proud to have been selected by Pfizer as the winner of the Pfizer Innovation Challenge" says Syncom CEO Ton Vries, Ph.D.  "This award is a clear recognition of the creativity and high quality of Syncom's scientific team.  It further exemplifies Syncom's motto of "Designing Chemistry" under which we provide our clients not only with materials but with high quality intellectual contributions to their projects as well.  We are looking forward to working with Pfizer on this and other program as part of our long lasting collaboration."

 

Pfizer congratulated Syncom on the high quality of their proposed solutions submitted in response to our second innovation challenge.  "Their response comprised a varied selection of routes and demonstrated superb innovation and creativity in the synthesis of a complex molecule.  We look forward to further collaborating with Syncom to develop this and other programs and consider Syncom a valued partner in the development of innovative research," said Pat O'Neill, Ph.D.:  Chemistry Team Leader, Pfizer Global Supply.

 

About Syncom

Founded in 1988, Syncom B.V. provides high quality and innovative custom manufacturing solutions to the global pharmaceutical industry.  Syncom custom synthesis services include small scale medicinal chemistry services, route scouting/process R&D activities and synthesis from mg to KG scale.  Syncom is recognized as a global leader in the field of chiral technologies.  Syncom's unique "Dutch resolution" technology and "Chirality First Time Right" approach exemplify Syncom's strong capabilities in the field of chiral technologies. 

04 August 2011

For Immediate Release:

Austin Chemical is proud to announce the exclusive representation of Micro Therapeutic Research Labs (MTR).   

MTR is a quality driven, full service Clinical Research Organization (CRO) that provides a broad range of clinical research services to the global pharmaceutical and biotechnology industry.  Located in Chennai India, MTR offers FDA inspected facilities and world-class services in compliance with GLP and cGMP that are robust and can be customized for your unique research requirements.

Operating state-of-the art research facilities, MTR offers over 240 beds to reduce cycle times and accelerate the delivery of life-enhancing drugs to market.  Over 400 BA/BE studies have been done to date, with more than 80% submitted to the FDA.  MTR can assist all your needs for bioavailability / bioequivalence studies, clinical research, statistical reporting and data management.

Download Spec Sheet